AI Multi-Horizon Analysis
No technical data available for short-term price action. Fundamentals are mixed with strong earnings but no insider buying. Liquidity concerns and lack of clear technical levels make direction uncertain.
Strong fundamental performance (revenue, net income) provides a bullish underpinning. However, lack of insider activity and tight liquidity (current ratio < 1) temper enthusiasm. The increased capex is a positive sign for future growth but could pressure near-term FCF.
Long-term outlook is bullish, driven by accelerating revenue growth, expanding net margins, and a strengthening balance sheet with significant retained earnings. Increased capital expenditures signal investment in future growth. The company's pricing power (high gross margins) and robust equity growth support a positive long-term view, despite the current liquidity constraint.
AstraZeneca shows strong fundamental growth with accelerating revenue and expanding net margins. However, the lack of technical data, neutral insider activity, and tight liquidity (current ratio < 1) create a balanced outlook. The company is financially robust but faces potential short-term liquidity risks. Long-term prospects are positive due to pipeline and strong balance sheet growth, but near-term price action is uncertain without technicals.
Detailed AI Fundamental Analysis
AZN (AstraZeneca PLC) – Fundamental Briefing
Date of analysis: Based on most recent filed data (20-F through Dec 2025, 6-K through Jun 2025)
Current price: $183.505 | Market cap: ~$303.6B | Employees: 96,100
Asset type: Common Stock (CS) – Primary listing NYSE, ADR-equivalent (UK domiciled)
Business Snapshot
AstraZeneca is a global science-led biopharmaceutical company focused on oncology, cardiovascular, respiratory, and rare disease therapies. The company has a strong pipeline and a large commercial footprint across developed and emerging markets. With a market cap above $300B, it is one of the largest pharma companies by value. No sector/industry detail was provided, but based on SEC filings (CIK 901832) it operates in the pharmaceutical industry.
Financial Trends (4-Period Trajectory)
Note: Periods include two annual (20-F) and two semi-annual (6-K) filings. Trends are shown for comparable fiscal year ends (Dec 2025 vs Dec 2024) and first halves (Jun 2025 vs Jun 2024). All figures in USD millions unless noted.
Revenue (implied = Gross Profit + Cost of Revenue)
| Period | Revenue | YoY Change |
|---|---|---|
| FY2025 (Dec 2025) | $58,739 | +8.6% vs FY2024 |
| FY2024 (Dec 2024) | $54,073 | – |
| H1 2025 (Jun 2025) | $14,457 | +11.7% vs H1 2024 |
| H1 2024 (Jun 2024) | $12,938 | – |
Revenue growth accelerating – H1 2025 grew 11.7% vs prior year H1, while annual FY2025 grew 8.6% vs FY2024, suggesting strengthening momentum through 2025.
Net Income & Margins
| Period | Net Income | Net Margin |
|---|---|---|
| FY2025 | $10,233 | 17.4% |
| FY2024 | $7,041 | 13.0% |
| H1 2025 | $2,448 | 16.9% |
| H1 2024 | $1,928 | 14.9% |
Net margin expansion – FY2025 net margin improved +440 bps vs FY2024. H1 2025 margin also rose +200 bps vs H1 2024. The absolute net income jump of 45% YoY (FY) reflects strong top-line growth and likely operating leverage or lower costs.
Gross Margin
| Period | Gross Margin |
|---|---|
| FY2025 | 81.9% |
| FY2024 | 81.1% |
| H1 2025 | 82.9% |
| H1 2024 | 83.1% |
Gross margin remains stable and high. The slight dip in H1 2025 vs H1 2024 (-20 bps) is negligible. Overall gross margin trend is steady, indicating pricing power and efficient production.
Balance Sheet Strength
| Metric | Dec 2025 | Dec 2024 | Jun 2025 | Jun 2024 |
|---|---|---|---|---|
| Total Assets | $114,074 | $104,035 | $112,422 | $104,340 |
| Total Liabilities | $65,355 | $63,164 | $67,612 | $64,742 |
| Shareholders' Equity | $48,719 | $40,871 | $44,810 | $39,598 |
| Current Assets | $28,723 | $25,827 | $28,939 | $25,393 |
| Current Liabilities | $30,617 | $27,866 | $33,536 | $28,566 |
| Retained Earnings | $10,972 | $3,160 | $7,023 | $1,847 |
| Current Ratio | 0.94 | 0.93 | 0.86 | 0.89 |
| Working Capital | -$1,894 | -$2,039 | -$4,597 | -$3,173 |
Equity is strengthening – Shareholders' equity grew 19.2% from Dec 2024 to Dec 2025, driven by retained earnings accumulation (from $3.16B to $10.97B, +247%). This indicates strong internal capital generation.
Liquidity remains tight but improving – Current ratio rose from 0.86 (Jun 2025) to 0.94 (Dec 2025), though still below 1.0. Working capital deficit narrowed to -$1.89B from -$4.60B earlier in 2025. The company relies on cash flow or long-term financing to cover short-term obligations – common for large pharma.
Asset base growing – Total assets +9.6% YoY (Dec vs Dec), likely from R&D investment, acquisitions, or internal growth.
Cash Flow (Capex Only)
| Period | Capital Expenditures |
|---|---|
| FY2025 | $2,810 |
| FY2024 | $1,924 |
| H1 2025 | $1,088 |
| H1 2024 | $799 |
Capex trending higher – FY2025 capex +46% vs FY2024. H1 2025 already $1.09B vs H1 2024 $0.80B. This suggests stepped-up investment in manufacturing or R&D infrastructure.
Note: Free Cash Flow not provided in the data.
Financial Health (Latest Period – Dec 2025)
AZN enters 2026 with a financially robust but liquidity-constrained profile:
- Profitability is strong: Net margin of 17.4% is a multi-year high, and net income more than doubled from 2022/2023 levels (implied trajectory). Retained earnings surged, indicating the company is retaining more earnings for reinvestment or debt paydown.
- Balance sheet leverage: Debt/Equity not reported, but total liabilities grew 3.5% YoY while equity grew 19.2%, so leverage is declining. The negative working capital is manageable given AZN’s consistent operating cash flow (not shown but inferred from net income + low capex relative to earnings).
- Capital spending increase: The capex ramp signals management’s confidence in future growth – likely related to new drug launches or manufacturing expansion.
- No insider transactions were reported in the last 90 days, giving no signal of management sentiment.
Key risk: The current ratio below 1.0 means AZN relies on cash from operations or credit lines to meet short-term obligations. A sudden disruption in revenue (e.g., patent cliff or regulatory setback) could stress liquidity.
Insider Activity
- No insider filings found in the periods specified (Feb 3 – May 4, 2026 and Apr 4 – May 4, 2026).
- Zero insider transactions over a 90-day window suggests either a quiet period or no material open-market trades. This is neutral – no insider buying to signal undervaluation, no selling to signal concern.
Multi-Timeframe Technical Context
No candle or indicator data was provided for any timeframe (1m to 1D). Therefore, we cannot assess short-term price action, support/resistance, volume trends, or momentum.
- Traders should incorporate their own chart analysis using current price of $183.51 and recent price history.
- Typical technical considerations for AZN include its long-term uptrend (stock has risen from ~$130 in 2023 to current levels) and the ADR nature – be aware of UK market correlation.
Bull / Bear Cases
Short-Term (Hours to Days)
| Bull | Bear |
|---|---|
| Company just reported strong FY2025 earnings (implied by net income jump) – positive catalyst momentum could carry price higher. | No insider buying suggests insiders see fair value or no near-term catalyst. Technical data missing – unable to confirm trend. |
| Improving current ratio and lower working capital deficit may reduce refinancing concerns. | Capex uptick could pressure near-term free cash flow (unknown magnitude). |
| – | Current ratio below 1.0 – any negative news could amplify sell-off due to liquidity perception. |
Long-Term (Weeks to Months)
| Bull | Bear |
|---|---|
| Revenue growth accelerating (11.7% in H1) and net margin expanding – fundamental momentum is strong. | Capital expenditure spike (+46% YoY) may not yield immediate returns – could weigh on FCF for 1-2 years. |
| Retained earnings ballooning to $11B provides internal funds for dividends, buybacks, or M&A without diluting equity. | Heavy reliance on oncology pipeline (not detailed here) – any pipeline setback could derail growth narrative. |
| Gross margin consistently above 80% indicates pricing power and limited generic erosion risk. | Negative working capital – while typical, a recession or credit tightening could worsen liquidity. |
| Strong equity growth (19% YoY) signals debt reduction or retained profit accumulation – balance sheet improving. | No insider buy activity to confirm management conviction. |
Key Levels & Triggers
| Item | Level / Event |
|---|---|
| Current Price | $183.51 |
| Key Support (to monitor) | Not available from data. Use recent swing lows (e.g., ~$170 area if visible from chart). |
| Key Resistance | Not available from data. Use recent highs (e.g., ~$190 area if visible). |
| Earnings Catalyst | Next earnings release date not provided. Expected ~Q2 2026 (July). Strong FY2025 results already priced? |
| Pipeline Catalyst | Phase 3 readouts or FDA decisions (e.g., for datopotamab deruxtecan, etc.) – not in data. |
| Dividend | AZN pays a dividend (ex-date typically Feb/Aug). Not provided here. |
| Macro | Pharma sector sentiment, UK economic data, USD/GBP movements affect ADR. |
Actionable triggers:
- Watch for insider filings – buying would be a strong bullish signal.
- Monitor next 6-K or 20-F for free cash flow disclosure – current data missing.
- Technical break above $185 likely needs volume confirmation (not provided).
This briefing is based solely on the data provided. No earnings guidance, valuation multiples, or analyst targets were included in the payload.
